Anti-Mouse PD-L1- Purified in vivo PLATINUM™ Functional Grade

Pricing & Details

Product No.P371
Clone
10F.9G2
Protein
PD-L1
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Programmed Death Ligand 1, B7-H1, PD-L1, CD274
Isotype
Rat
IgG2b κ
Applications
B
,
CODEX®
,
FA
,
IHC FF
,
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
P371-1.0 mg
1.0 mg
$225.00
In stock
Max:
Min: 1
Step: 1
P371-5.0 mg
5.0 mg
$445.00
In stock
Max:
Min: 1
Step: 1
P371-25 mg
25 mg
$1,285.00
In stock
Max:
Min: 1
Step: 1
P371-50 mg
50 mg
$2,045.00
In stock
Max:
Min: 1
Step: 1
P371-100 mg
100 mg
$2,800.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Rat
Immunogen
Mouse CD274
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone 10F.9G2 recognizes an epitope on mouse PD-L1.
Antigen Distribution
PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

Antigen Details

Protein
Ligand/Receptor
PD-1 (PDCD1)
PubMed
NCBI Gene Bank ID
Research Area
Cancer
.
Costimulatory Molecules
.
Immunology

References & Citations

1. Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed
2. Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.
3. Freeman, G. et al. (2000) J. Exp. Med. 192:1027.
IHC
General Western Blot Protocol

Formats Available